Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPM1 | P06748 | 1/20 | 0.43 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 6/20 | 0.43 |
| ▸ | NPC1 | O15118 | 5/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.41 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RPA1 | P27694 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2031021 | 0.83 | MAPT (0.43) | RAB9ANPC1SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL5214295 | 0.82 | AURKA (0.45) | RAB9ANPC1SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL2033721 | 0.80 | AHR (0.40) | RAB9ANPC1SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL2030860 | 0.80 | KMT2A (0.41) | RAB9ANPC1SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL11316335 | 0.79 | HRH3 (0.55) | RAB9ANPC1SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL6821435 | 0.77 | RAB9A (0.45) | RAB9ANPC1SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL9959009 | 0.74 | SNCA (0.42) | RAB9ANPC1SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL2885857 | 0.72 | NPC1 (0.43) | NPM1ALKRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL12543987 | 0.70 | ALDH1A1 (0.50) | RAB9ANPC1SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL16212302 | 0.70 | RAB9A (0.72) | RAB9ANPC1SMN1; SMN2ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9567355-B2 | Hepatitis C inhibitors and uses thereof | ABBVIE INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-20160355530-A1 | HEPATITIS C INHIBITORS AND USES THEREOF | ABBVIE INC. | 2016-12-08 | — | — | US | disclosed |
| US-9493456-B2 | Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators | UNIVERSITE DE MONTREAL (CA) | 2016-11-15 | — | — | US | disclosed |
| US-9493456-B2 | Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators | UNIVERSITE DE MONTREAL (CA) | 2016-11-15 | — | — | US | disclosed |
| US-9493456-B2 | Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators | UNIVERSITE DE MONTREAL (CA) | 2016-11-15 | — | — | US | disclosed |
| US-9453007-B2 | Hepatitis C inhibitors and uses thereof | ABBVIE INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-20160002213-A1 | HEPATITIS C INHIBITORS AND USES THEREOF | ABBVIE INC. | 2016-01-07 | — | — | US | disclosed |
| US-9173887-B2 | Hepatitis C inhibitors and uses thereof | ABBVIE INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150197520-A1 | PYRAZOLOPYRIDINE AND PYRAZOLOPYRIMIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | Université de Montréal | 2015-07-16 | — | — | US | disclosed |
| US-20150197520-A1 | PYRAZOLOPYRIDINE AND PYRAZOLOPYRIMIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | Université de Montréal | 2015-07-16 | — | — | US | disclosed |
| US-9018395-B2 | Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators | Université de Montréal (CA) | 2015-04-28 | — | — | US | disclosed |
| US-20140057894-A1 | PYRAZOLOPYRIDINE AND PYRAZOLOPYRIMIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | UNIVERSITE DE MONTREAL (CA) | 2014-02-27 | — | — | US | disclosed |
| US-20140057894-A1 | PYRAZOLOPYRIDINE AND PYRAZOLOPYRIMIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | UNIVERSITE DE MONTREAL (CA) | 2014-02-27 | — | — | US | disclosed |
| US-20140057894-A1 | PYRAZOLOPYRIDINE AND PYRAZOLOPYRIMIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | UNIVERSITE DE MONTREAL (CA) | 2014-02-27 | — | — | US | disclosed |
| US-20140038919-A1 | HEPATITIS C INHIBITORS AND USES THEREOF | ABBVIE INC. (US) | 2014-02-06 | — | — | US | disclosed |
| EP-2655362-A1 | HEPATITIS C INHIBITORS AND USES THEREOF | Abbvie Inc. (US) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012100342-A1 | PYRAZOLOPYRIDINE AND PYRAZOLOPYRIMIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | Université de Montréal (CA) | 2012-08-02 | — | — | WO | disclosed |
| WO-2012100342-A1 | PYRAZOLOPYRIDINE AND PYRAZOLOPYRIMIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | Université de Montréal (CA) | 2012-08-02 | — | — | WO | disclosed |
| WO-2012087833-A1 | HEPATITIS C INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012084860-A1 | COMPONENT CONNECTION HAVING A THERMOPLASTIC FOAM SEAL | BAYER MATERIALSCIENCE AG (DE) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150197520-A1 | PYRAZOLOPYRIDINE AND PYRAZOLOPYRIMIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | MC4R, MC5R, MC1R | NPM1 3336/4885ALK 1638/4885RAB9A 1193/4885 |
| US-20160002213-A1 | HEPATITIS C INHIBITORS AND USES THEREOF | HAVCR2, HCCS, SLC10A1 | NPM1 2810/4885ALK 3747/4885RAB9A 1331/4885 |
| US-20140038919-A1 | HEPATITIS C INHIBITORS AND USES THEREOF | HAVCR2, HCCS, SLC10A1 | NPM1 2810/4885ALK 3747/4885RAB9A 1331/4885 |
| US-20140057894-A1 | PYRAZOLOPYRIDINE AND PYRAZOLOPYRIMIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | MC4R, MC5R, MC1R | NPM1 3409/4885ALK 1970/4885RAB9A 1125/4885 |
| US-20160355530-A1 | HEPATITIS C INHIBITORS AND USES THEREOF | HAVCR2, HCCS, SLC10A1 | NPM1 2810/4885ALK 3747/4885RAB9A 1331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.